Brief: Cassava Sciences Q2 Basic EPS USD -0.63
03/08/2023 14:07
Aug 03 (Reuters) - Cassava Sciences Q2 operating income USD -28.777 million. * Q2 operating expenses USD 28.777 million * Q2 net income USD -26.376 million
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing